DTC Ads Need Tabular Presentation Of Efficacy Data, Health Affairs Article Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Showing how well a product works could temper demand for drugs, article suggests, since consumers often have an exaggerated sense of benefits. The study of modified ads for Pravachol, Vioxx and Plavix found that people thought less of a drug’s efficacy when ads contained a “benefits box.”
You may also be interested in...
Alternatives To Brief Summary Outlined In Draft Guidance
One of FDA's three draft guidances on DTC advertising requests that consumer-friendly language be used. Commissioner McClellan calls proposed brief summary alternatives a "win-win" and suggests manufacturers will be able to reduce their advertising costs as a result.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.